OBJECTIVES: Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients. BACKGROUND: The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear. METHODS: A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months. RESULTS: The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003). CONCLUSIONS:Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.
RCT Entities:
OBJECTIVES: Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients. BACKGROUND: The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear. METHODS: A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months. RESULTS: The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003). CONCLUSIONS: Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.
Authors: David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman Journal: Can J Cardiol Date: 2006-06 Impact factor: 5.223
Authors: N Asdaghi; J I Coulter; J Modi; M C Camden; A Qazi; M Goyal; T Rundek; S B Coutts Journal: AJNR Am J Neuroradiol Date: 2015-04-23 Impact factor: 3.825
Authors: Kausik K Ray; Babak Nazer; Richard Cairns; C Michael Gibson; Christopher P Cannon Journal: J Thromb Thrombolysis Date: 2010-07 Impact factor: 2.300
Authors: Viktor Hamrefors; Marju Orho-Melander; Ronald M Krauss; Bo Hedblad; Peter Almgren; Göran Berglund; Olle Melander Journal: J Lipid Res Date: 2009-09-22 Impact factor: 5.922
Authors: José M A Lobos Bejarano; Miguel Angel Royo-Bordonada; Carlos Brotons; Luís Alvarez-Sala; Pedro Armario; Antonio Maiques; Dídac Mauricio; Susana Sans; Fernando Villar; Angel Lizcano; Antonio Gil-Núñez; Fernando de Alvaro; Pedro Conthe; Emilio Luengo; Alfonso Del Río; Olga Cortés; Ana de Santiago; Miguel A Vargas; Mercedes Martínez; Vicenta Lizarbe Journal: Aten Primaria Date: 2009-07-15 Impact factor: 1.137